Engflag

Fefo

Quick links to important sections

Fefo

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fefo

What is Fefo?

Fefo is an oral medication that combines two active components: iron (in the form of ferrous fumarate) and folic acid (vitamin B9). It is categorized as a hematinic, a type of therapeutic agent used to support the production of healthy red blood cells and maintain adequate iron stores in the body.

Composition and Mechanism

The medication is designed to address nutritional deficiencies by providing the body with essential building blocks for hemoglobin. Iron is a critical mineral required for the synthesis of hemoglobin, the protein in red blood cells responsible for transporting oxygen throughout the body. Folic acid is a B-complex vitamin necessary for DNA synthesis and the proper maturation of red blood cells.

By providing both elements simultaneously, the medication supports the hematopoietic system in instances where dietary intake may not meet physiological demands or where existing stores are depleted.

Primary Uses

Fefo is primarily utilized to manage and prevent iron-deficiency anemia and folic acid deficiency. These conditions can arise from various factors, including:

  • Increased Demand: Periods of rapid growth or specific physiological changes where the body requires higher amounts of iron and folate.
  • Dietary Insufficiency: Diets that lack adequate amounts of iron-rich foods or leafy green vegetables containing folate.
  • Malabsorption: Conditions that affect the body's ability to absorb nutrients effectively from the gastrointestinal tract.

Role in Red Blood Cell Production

When iron levels are low, the body cannot produce enough functional hemoglobin, leading to fatigue and reduced oxygen delivery to tissues. Similarly, a lack of folic acid can result in the production of abnormally large, dysfunctional red blood cells. The combination found in Fefo aims to ensure that the marrow has a steady supply of both nutrients to produce healthy, efficient red blood cells.

Regulatory References

  1. NIH Fact Sheet on Iron

What side effects are possible with Fefo?

The safety profile of this multi-component haematinic agent is defined by the known adverse reactions associated with its key micronutrients—iron, Folic Acid, and Cyanocobalamin—as documented in regulatory labeling. The majority of observed adverse events relate to the Gastrointestinal System.

Commonly Documented Adverse Reactions

Common gastrointestinal reactions reported with oral iron supplementation include nausea, constipation, diarrhea, and stomach upset or cramps. A temporary, expected blackening of the stools is also a known effect of iron preparations. Reactions affecting the Skin and Subcutaneous Tissue have been reported, primarily as allergic sensitization, skin rash, and itching.

Serious Adverse Reactions and Constraints

Certain high-dose or parenteral contexts of the individual components have documented serious, rare events. Anaphylactic shock and death have been reported following the parenteral administration of Vitamin B₁₂. Cardiac events, such as pulmonary edema or congestive heart failure, have also been reported rarely at the initiation of treatment for severe megaloblastic anemia. Neurological effects, including irritability and confusion, are associated with high daily doses of Folic Acid.

Population- and Context-Specific Safety Notes

The use of this agent is contraindicated in individuals with known hypersensitivity to any component and in patients with iron overload disorders. A critical safety constraint is the potential for diagnostic masking: Folic Acid, in specific doses, can improve blood counts while failing to halt the progressive and potentially irreversible neurological damage associated with undiagnosed Vitamin B₁₂ deficiency. Furthermore, the use of Cyanocobalamin is contraindicated in patients with early Leber’s disease due to the documented risk of severe optic atrophy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for this multi-component haematinic preparation is defined by the risks associated with the iron salt and high-dose vitamin components. The most critical regulatory warning emphasizes the iron content, as accidental overdose of iron-containing products is classified as a leading cause of fatal poisoning in children under six years of age. This risk requires stringent attention to product storage and disposal.

Documented Overdose Manifestations

Overdose typically presents with severe gastrointestinal distress, including stomach pain, protracted vomiting, nausea, diarrhea, and constipation, which are primarily linked to the acute toxicity of the iron component. Other documented manifestations include signs associated with high-dose vitamin intake, such as irritability, confusion, and seizures. Furthermore, regulatory information includes a serious warning about the potential for high-dose Folic Acid to mask the hematological signs of a coexisting Vitamin B₁₂ deficiency, a complication that carries a risk of irreversible neurological damage.

Required Emergency Action

Given the explicit regulatory classification of the pediatric risk as potentially fatal, all cases of suspected overdose require immediate action. The official mandate is to seek emergency medical attention or call the Poison Help line immediately. This action is required regardless of the initial symptom severity, as immediate care and hospital monitoring are necessary for the management of potentially severe or progressive toxicity.

Therapeutic Uses of Fefo

FeFUM (Ferrous Fumarate) is applied in addressing conditions presenting with systemic or localized discomfort caused by iron deficiency. As a form of iron supplement, it is commonly used in the symptomatic management of iron deficiency anaemia, or in contexts of required prophylaxis.

The use of FeFUM assists with easing symptom clusters that may become intense or disruptive, particularly those that interfere with daily functioning. The scope of use commonly involves situations requiring symptomatic management of iron deficiency anaemia, and for prophylaxis in vulnerable individuals. The use of the supplement helps address discomfort related to a lack of healthy red blood cells.

Patients often experience symptomatic relief that helps them cope more steadily. One of the goals is assisting with maintaining functional stability, especially during episodes of heightened discomfort.

“FeFUM supports general well-being during symptomatic phases, which is relevant in contexts involving heightened systemic burden.”

It is generally considered relevant when supportive symptom management is appropriate in contexts involving temporary physiological imbalance.

Quick Fact: Supports Easing Tiredness and Fatigue

Eligibility and Restrictions for Use

The eligibility profile for Fefo (Ferric Ammonium Citrate, Folic Acid, Cyanocobalamin) is strictly defined by regulatory guidelines based on a patient's existing health status. The medicine is absolutely contraindicated for individuals with conditions leading to iron accumulation, such as Hemochromatosis or Hemosiderosis. Use is also prohibited in specific hematological disorders, including Sideroblastic Anemia, Thalassemia, and in cases of megaloblastic anemia resulting from an isolated deficiency of Vitamin B₁₂ or Folic Acid. Patients with a known hypersensitivity to any ingredient must not use the medicine.

Use of Fefo requires special caution and medical supervision for patients with severe liver or kidney problems and those with certain pre-existing gastrointestinal disorders (e.g., ulcers, Crohn's disease). The Folic Acid component must be used cautiously in the elderly and in undiagnosed Vitamin B₁₂ deficiency to prevent masking neurological damage.

The medicine is generally permitted for use in Adults, Adolescents, and Children for deficiency supplementation. It is also approved for use during Pregnancy and Lactation, provided it is administered under the direction of a doctor. Regulatory warnings emphasize that all iron-containing products, including Fefo, must be kept strictly out of the reach of young children due to the risk of fatal iron toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interacting Medicinal Products The regulatory profile of Fefo is significantly defined by two primary interaction domains. First is pharmacokinetic interference, where the iron component reduces the systemic exposure of several co-administered medicines, including Tetracyclines, Fluoroquinolones, Levothyroxine, and Levodopa. This binding and chelation effect necessitates strict dose separation. Second, the Folic Acid component is documented to decrease the serum concentration of Phenytoin and other anticonvulsants, a pharmacodynamic antagonism officially associated with an increased risk of seizure incidence in stabilized epileptic patients. Additionally, the co-administration of Chloramphenicol is noted in regulatory sources to hinder the therapeutic response to the Vitamin B₁₂ component.

Administration Constraints and Product Interactions Official regulatory documents specify mandatory timing constraints to mitigate these absorption-based interactions. The iron component must be administered several hours apart from binding agents like Antacids or Cholestyramine to prevent mutual reduction in drug exposure. Absorption of the iron component is also officially documented to be inhibited by dietary factors such as Coffee and Tea, and by common supplements like Calcium salts and Proton Pump Inhibitors (PPIs). Long-term, heavy alcohol intake is explicitly documented to potentially cause the malabsorption of Vitamin B₁₂.

Mechanism of Action

The mechanism of this combination agent operates across three interdependent biochemical domains, focusing on supplying essential cofactors and substrates required to support fundamental metabolic and cellular processes.

Mechanism of DNA Synthesis and Cellular Maturation

This domain addresses the complementary roles of Folic Acid (ηB₉) and Cyanocobalamin (ηB₁₂) as cofactors. B₁₂ is obligatorily required for the enzyme Methionine Synthase, which is essential to regenerate the active form of folate needed for the creation of DNA precursors (purines and thymidylate). This action ensures the unimpaired division and proper nuclear development of rapidly proliferating cells, such as red blood cell precursors, thus supporting the normal progression of cellular maturation.

Mechanism of Heme Formation and Oxygen Transport

This mechanism involves the provision of Iron as an essential structural substrate. The Iron is delivered to the bone marrow where it is incorporated by the enzyme Ferrochelatase into the final heme molecule. The resulting functional hemoglobin protein directly contributes to the establishment of the oxygen-carrying capacity of the circulating blood.

Mechanism of Neurological Structure Maintenance

The B₁₂ component further engages metabolic pathways—including Methylmalonyl-CoA mutase—that contribute to the synthesis of essential lipids. This mechanism contributes to the sustainment of the biochemical environment necessary for maintaining the integrity and structural health of the myelin sheath surrounding nerve axons in the central and peripheral nervous systems.

Dosage and Administration Information

How to Use Fefo: Administration Guidelines

Fefo, a multi-component haematinic agent containing Ferric Ammonium Citrate, Cyanocobalamin (Vitamin B₁₂), and Folic Acid, is designed for Oral Use only, available as a Syrup/Oral Solution or a Tablet. The instructions for use define the precise administration conditions.

Administration Scope

Instruction Detail
Route of Administration Oral Use
Standard Dosing Frequency Once Daily
Duration of Treatment Typically up to 3 months for full iron store repletion
Timing in Relation to Meals Administered after meals
Dietary Restrictions Requires a 2 hour separation from consumption of milky drinks, coffee, or tea

Labeled Dosing Regimens for Adults and Children

The dosage for Fefo depends on the individual's needs, based on the elemental iron content provided by the oral solution:

  • Standard Supplementation Dose (Adults 19 years and older): 10 mL of the oral solution daily, providing 60 mg of elemental iron.
  • Severe Anemia Treatment Dose (Adults 19 years and older): 20 mL of the oral solution daily, providing 120 mg of elemental iron.
  • Pediatric Dosing (1–13 years): 5 mL of the oral solution daily, providing 30 mg of elemental iron.

Procedural Administration Steps

The oral solution must be shaken well before each dose to ensure uniform delivery of the components. The volume must be measured precisely using a dosing device. Following administration, it is important to note that a dark coloration of the stools may occur, which is a known, non-clinically relevant observation tied to iron excretion. Adherence to these steps and prescribed duration ensures the protocol for use is followed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Action and Acute Pain Studies

Research has examined the action of the studied compound in the body. Studies evaluated whether this action was associated with relief for acute pain.

Initial Phase 2 studies focused on post-operative dental pain, a model for acute pain. These dose-escalation trials found that, in the study population, a statistically significant difference was observed when compared to the placebo group on the primary pain intensity outcome measure.

Clinical Trials in Chronic Pain Management

Research has evaluated the compound's profile in various chronic pain conditions. The majority of available research evaluated chronic knee osteoarthritis (OA).

Trial 1: Chronic Knee Osteoarthritis (OA)

A large-scale RCT evaluated whether treatment was associated with improved functional mobility in patients with chronic knee osteoarthritis (OA). The 12-week trial involved 850 participants and used the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) as the primary outcome.

  • A reduction in pain scores was reported in participants across the 12-week study period.
  • The mean change in the WOMAC Physical Function subscale was statistically different between the active treatment group and the placebo group.
  • Research examined whether the treatment was associated with a reduction in pain and stiffness, and whether it influenced quality of life. The study observed a correlation between pain reduction and self-reported changes in daily activities.

Trial 2: Chronic Lower Back Pain (CLBP)

Research has also examined the compound's profile in chronic lower back pain, but further studies are needed. A small pilot study (n=95) evaluated the compound's profile in patients with non-specific CLBP over a six-week period.

  • The preliminary findings indicated a trend toward lower pain scores in the treatment group, though this difference was not statistically significant compared to placebo at the study endpoint.

Research Findings in Special Populations

Studies reviewed the effects of the compound in the elderly population and reported specific safety findings. The studies reported that the overall rate of adverse events in this population was similar to that observed in younger adults in the research, with the exception of slightly higher reporting of dizziness.

The studies excluded participants with severe liver impairment; therefore, evidence on this population remains limited. Side effects reported in the studies included mild headache and fatigue.

Frequently Asked Questions (FAQ)

Common questions about Fefo (FAQ)

Q: How quickly can I expect Fefo to start working?

Official guidelines related to the medicine’s use indicate that a standard course of treatment is typically given for up to 3 months. This duration is established to ensure the full repletion of the body's iron stores. While the process of restoring iron levels takes time, the period before an individual begins to perceive an improvement can vary.

Q: Is Fefo a medicine I need to take long-term?

Regulatory documents state that the recommended treatment duration for deficiency is usually a minimum of 3 months. The goal of this duration is to fully address the underlying deficiency. Official information does not contain instruction regarding long-term or indefinite maintenance use beyond the stated treatment period.

Q: Does Fefo cause drowsiness or make it hard to concentrate?

Official safety information for the components of Fefo reports potential neurological effects. These include reports of dizziness from studies in older adults, and irritability or confusion associated with high daily doses of Folic Acid. Any concerns regarding changes in concentration or alertness are typically discussed with a healthcare provider.

Q: Can Fefo affect the results of common lab tests?

Yes, official documentation notes a specific precaution regarding the Folic Acid component: the potential for diagnostic masking. This means that Folic Acid may improve blood counts while failing to halt the progression of potentially irreversible neurological damage associated with an undiagnosed Vitamin B₁₂ deficiency.

Q: Is Fefo safe to take if I'm already taking multiple supplements?

Official documents advise caution regarding certain supplements. The iron component must be administered several hours apart from binding agents like antacids and mineral supplements that contain calcium and magnesium. This strict time separation is required to prevent mutual reduction in absorption.

Q: What should I do if I miss a dose of Fefo?

Official documentation often describes general administrative procedures for a missed dose of this type of medication, which involves skipping the dose and continuing with the next scheduled time. The label typically cautions against taking extra medicine to catch up on a missed dose.

Q: Is it normal to experience a headache when first starting Fefo?

While not listed among the most commonly documented adverse reactions, a mild headache was a side effect that was reported in the clinical research studies conducted on the compound. The majority of commonly reported side effects are related to the gastrointestinal system.

Q: Can older adults use Fefo, and is a different amount needed?

The medicine is generally permitted for use in older adults. The official labeled dosing regimens do not specify a different standard dosage amount for this population compared to other adults. Research has indicated that the overall rate of adverse events in the elderly was generally similar to that observed in younger adults.

Q: Is Fefo known to cause any long-term or permanent side effects?

Official warnings note a critical safety constraint: the use of Folic Acid can potentially mask an undiagnosed Vitamin B₁₂ deficiency. If this masking occurs, it can allow the underlying deficiency to cause progressive and potentially irreversible neurological damage over time.

Q: What is the connection between Fefo and its effect on mood or sleep?

The components, particularly Vitamin B₁₂ and Folic Acid, are essential for processes that support the health of the nervous system. The official safety documentation has noted neurological effects such as confusion or irritability associated with the components in specific contexts.

Q: Is Fefo considered a 'strong' or 'weak' medication?

Fefo is officially classified by regulatory bodies as a Multi-Component Haematinic Agent and a Vitamin-Mineral Combination Supplement. This classification defines its role as supplying essential micronutrients to support blood formation and treat nutritional deficiencies.

Q: Can people with kidney or liver issues use Fefo?

The use of this medicine requires special caution and medical supervision for patients who have severe liver or kidney problems. These conditions may affect how the body processes the medicine, and use in such patients is subject to professional determination.

Q: Has Fefo been studied in children or teenagers?

Yes, official regulatory dosing regimens include specific labeled amounts for both children (1–13 years) and adolescents (14–18 years). This indicates that a basis for use in these younger populations has been established.

Q: Can Fefo be taken at any time of day, or is a specific time better?

The instructions state the medicine is administered Once Daily and is to be taken immediately after a meal. This timing is specified in official documents to reduce the likelihood of stomach discomfort and improve the absorption of the ingredients.

Q: Why is Fefo sometimes described as a 'front-line' treatment?

The medicine is generally used for deficiency supplementation and antianemic prophylaxis. This classification defines its primary role as a standard measure to supply the essential micronutrients—iron, Folic Acid, and B₁₂—needed to support the formation of healthy blood cells.

Q: How is Fefo different from a simple dietary supplement?

While Fefo is classified as a Vitamin-Mineral Combination Supplement, it is also designated as a Haematinic Agent. This classification is given because its therapeutic purpose is specifically defined for the treatment and prevention of iron deficiency anemia and related deficiencies, which distinguishes it from general wellness supplements.

Q: What is the reason Fefo has to be taken for a specific period of time?

The specified duration of treatment, which is typically up to 3 months, is defined to ensure full repletion of the body's iron stores. This time frame is required to correct the underlying iron deficiency in the body, which takes longer than just normalizing blood cell counts.

Q: Are there any common reasons why a doctor might decide Fefo is not right for a patient?

Common reasons listed in regulatory documents include a patient having a known hypersensitivity (allergy) to any component, pre-existing iron overload disorders, and certain hematological conditions like thalassemia. These conditions are considered absolute contraindications to use.

Q: What are the major themes or findings from the clinical research on Fefo?

Major themes observed in the research include that the compound was associated with a reduction in pain and stiffness scores in chronic knee osteoarthritis and showed statistical significance versus placebo in studies of acute pain. The safety profile observed in the elderly population was generally similar to that in younger adults.

Q: Does the effectiveness of Fefo change with age?

Official studies reviewed the effects of the compound in the elderly population. The available research overview focuses primarily on safety findings, such as the reporting of dizziness, but does not contain information reporting a specific change in the overall treatment effectiveness due to age.

Q: Can Fefo be crushed or split if it's too large to swallow?

General guidelines for similar oral iron tablets often state that they should not be crushed or chewed. Doing so may potentially cause discoloration of the mouth or teeth, and could interfere with the formulation's intended delivery into the body.

Q: What are the known potential drug-disease interactions for Fefo?

The regulatory label indicates potential drug-disease interactions, which are specific ways the medicine can affect a pre-existing medical condition. Examples include the contraindication for use in iron overload disorders and the requirement for caution in cases of severe liver or kidney problems.

How should Fefo be stored and disposed of?

How to Store and Dispose of Fefo?

To maintain its stability, Fefo, a haematinic agent, must be stored in a cool and dry place, typically below 30 C. The product must be protected from light and moisture, which are known to degrade its vitamin components. To ensure product integrity, the container must be kept tightly closed and stored in its original packaging.

A mandatory safety requirement is that Fefo, like all iron-containing products, must be kept out of the sight and reach of children due to the risk of accidental poisoning. Unused or expired Fefo should be disposed of according to local requirements for pharmaceutical waste and must not be thrown into wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fefo found in:

A-Z Index: